Ansuvimab is a recombinant human monoclonal antibody with antiviral activity against Zaire ebolavirus.
Ansuvimab exposure-response relationship and the time course of pharmacodynamic response is unknown.
Limited data from 18 healthy subjects 22 to 56 years of age suggests that the pharmacokinetic profile of ansuvimab is consistent with the profile of other IgG1 monoclonal antibodies.
Pharmacokinetic data are not available for Zaire ebolavirus infected patients.
The effect of age, renal impairment or hepatic impairment on the pharmacokinetics of ansuvimab is unknown.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
